View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 22, 2020

SOM Biotech identifies three Covid-19 drug candidates

SOM Biotech has completed in-vitro analysis and identified three drug candidates that can be potentially used to treat Covid-19.

SOM Biotech has completed in-vitro analyses and identified three drug candidates that can be potentially used to treat Covid-19.

The three candidates inhibit the main protease of SARS-CoV-2, which causes Covid-19, in turn targeting the virus’ replication.

SOM Biotech partnered with Ewha Woman’s University in South Korea for Covid-19 research.

The company’s artificial intelligence (AI)-based screening technology, SOMAIPRO, was used to discover the inhibitors of 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV. These inhibitors were intended to offer potential Covid-19 treatments.

Ewha Woman’s University professor Dong-Hae Shin said: “We are very proud about working on promising Covid-19 treatments and contributing to finding effective, safe and fast solutions due to the importance of the current pandemic situation.

“We decided to start working with SOM Biotech as we are committed to tackling this Covid-19 pandemic leveraging on partners with innovative technologies and excellent know-how.”

Of the three in-vitro validated candidates, Eravacycline is an approved drug while Prexasertib is currently in clinical development and Cynarine is a natural compound used as a dietary supplement.

All three drug candidates can be repurposed to treat Covid-19, said the company.

The company also filed a patent application for method-of-use protection for the three compounds globally.

SOM Biotech CEO and founder Raul Insa said: “We have joined forces with professor Dong-Hae Shin from Ewha Woman’s University to combine our scientific and medical expertise to find new therapies for the treatment of Covid-19.

“Thanks to our capabilities in screening molecules with our AI-based technology, we have validated active anti-coronavirus compounds. Thus, we look forward to the rapid development of these drugs to be able to provide patients with an effective and safe treatment against the Covid-19 as soon as possible.”

The company said that clinical studies of these drug candidates can be launched immediately.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy